• SynAct Pharma won a favorable U.S. PTAB appeal covering an immediate-release oral tablet formulation of resomelagon (AP1189-acetate).
• The decision supports patentability versus obviousness arguments, strengthening IP protection around the company’s lead program.
• SynAct previously received U.S. patents covering resomelagon’s crystal form, including one with adjusted term running to July 2, 2044.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SynAct Pharma AB published the original content used to generate this news brief on August 05, 2026, and is solely responsible for the information contained therein.